New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
07:22 EDTSUPNSupernus price target raised to $14 from $12 at Stifel
After Supernus stated that it believes it is on track to reach cash flow break-even, Stifel thinks the launches of the company's Oxtellar and Trokendi drugs are going well. Stifel believes that uptake of the company's Trokendi XR drug could improve, and it keeps a Buy rating on the stock.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
16:05 EDTSUPNSupernus court win removes an overhang, says Northland
Subscribe for More Information
15:03 EDTSUPNCourt rules in favor of Supernus on two patents in suit with Actavis
The U.S. District Court for the District of New Jersey entered judgment against Actavis, now known as Allergan (AGN), and in favor of Supernus (SUPN) as to the '898 and '131 patents disputed in a lawsuit between the two companies. The court found against Supernus and in favor of Actavis as to the '600 patent, according to a court filing. The Patents-in-Suit relate to Supernus' Oxtellar XR drug indicated for the treatment of seizures. Shares of Supernus are up 29% in afternoon trading following the court ruling.
14:53 EDTSUPNSupernus jumps 21%, halted for circuit-breaker

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use